Terns Pharmaceuticals (TERN) to Release Earnings on Monday

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect Terns Pharmaceuticals to post earnings of ($0.29) per share for the quarter.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06. On average, analysts expect Terns Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Terns Pharmaceuticals Stock Up 0.5 %

Shares of TERN traded up $0.02 during midday trading on Wednesday, reaching $3.03. The company had a trading volume of 602,074 shares, compared to its average volume of 1,536,589. The firm has a 50 day simple moving average of $2.92 and a 200-day simple moving average of $4.67. Terns Pharmaceuticals has a 1-year low of $1.87 and a 1-year high of $11.40. The stock has a market cap of $264.19 million, a PE ratio of -2.56 and a beta of -0.16.

Analyst Ratings Changes

Several analysts have recently weighed in on TERN shares. JMP Securities restated a "market outperform" rating and set a $20.00 price objective on shares of Terns Pharmaceuticals in a research report on Monday, April 21st. William Blair reissued a "market perform" rating on shares of Terns Pharmaceuticals in a research report on Friday, March 21st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $18.38.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.